PALB2 and breast cancer: As a result, patients considering RRM later in life will have already lived through a significant percentage of their cumulative risk and should be counselled accordingly; for example, a 70-year-old unaffected BRCA1/2 or PALB2 carrier harbors less than a 30% residual breast cancer risk to the age of 80 and may wish to consider enhanced surveillance over surgical prophylaxis.